PURPOSE: TACE induces variable systemic effects by producing factors that promote inflammation, oncogenesis, and angiogenesis. Here we compare concentrations of microRNAs (miR-21, miR-210 and miR-34a) and vascular endothelial growth factor (VEGF) in hepatocellular carcinoma (HCC) patients undergoing TACE with degradable (DSM) and nondegradable (DEB) particles and potential use of these biomarker changes for prediction of patient outcomes. MATERIALS AND METHODS: Overall, 52 patients with HCC treated with DSM TACE (24 patients) and DEB TACE (28 patients) were included in this prospective study. Concentrations of studied biomarkers were measured from blood plasma preprocedurally, immediately (< 90 min) postprocedurally, and 24-h after TACE. Levels were compared between DSM and DEB TACE and correlated with treatment response six and 12 months after the first TACE. RESULTS: Both DSM and DEB TACE elevated plasma levels of miR-21, miR-34a, and miR-210 at 24 h post-procedure compared to baseline levels (FC 1.25-4.0). MiR-34a elevation immediately after TACE was significantly associated with nonprogressive disease compared to those with progressive disease at both six months (FCa: p = 0.014) and 12 months (FCa: p = 0.029) post-TACE. No significant biomarker changes were found between the embolization particle groups. However, VEGF levels showed a decrease only in the DSM TACE group (FC24: p = < 0.001). CONCLUSION: Embolization particle type did not significantly impact miRNA or VEGF changes post-TACE. However, miR-34a elevation immediately after the procedure predicts better patient outcome and may prove useful as a biomarkers for the monitoring of clinical outcomes. LEVEL OF EVIDENCE: Level 3 Prospective cohort study.

• MeSH
• Biomarkers blood   MeSH
• Chemoembolization, Therapeutic * methods   MeSH
• Carcinoma, Hepatocellular * therapy   blood   genetics   MeSH
• Middle Aged MeSH
• Humans MeSH
• MicroRNAs * blood   MeSH
• Biomarkers, Tumor * blood   MeSH
• Liver Neoplasms * therapy   genetics   blood   MeSH
• Prospective Studies MeSH
• Aged MeSH
• Vascular Endothelial Growth Factor A * blood   MeSH
• Treatment Outcome MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH

OBJECTIVE: Research suggests that disrupted interoception contributes to the development and maintenance of functional neurological disorder (FND); however, no functional neuroimaging studies have examined the processing of interoceptive signals in patients with FND. METHODS: The authors examined univariate and multivariate functional MRI neural responses of 38 patients with mixed FND and 38 healthy control individuals (HCs) during a task exploring goal-directed attention to cardiac interoception-versus-control (exteroception or rest) conditions. The relationships between interoception-related neural responses, heartbeat-counting accuracy, and interoceptive trait prediction error (ITPE) were also investigated for FND patients. RESULTS: When attention was directed to heartbeat signals versus exteroception or rest tasks, FND patients showed decreased neural activations (and reduced coactivations) in the right anterior insula and bilateral dorsal anterior cingulate cortices (among other areas), compared with HCs. For FND patients, heartbeat-counting accuracy was positively correlated with right anterior insula and ventromedial prefrontal activations during interoception versus rest. Cardiac interoceptive accuracy was also correlated with bilateral dorsal anterior cingulate activations in the interoception-versus-exteroception contrast, and neural activations were correlated with ITPE scores, showing inverse relationships to those observed for heartbeat-counting accuracy. CONCLUSIONS: This study identified state and trait interoceptive disruptions in FND patients. Convergent between- and within-group findings contextualize the pathophysiological role of cingulo-insular (salience network) areas across the spectrum of functional seizures and functional movement disorder. These findings provide a starting point for the future development of comprehensive neurophysiological assessments of interoception for FND patients, features that also warrant research as potential prognostic and monitoring biomarkers.

• MeSH
• Adult MeSH
• Interoception * physiology   MeSH
• Middle Aged MeSH
• Humans MeSH
• Magnetic Resonance Imaging MeSH
• Brain Mapping MeSH
• Young Adult MeSH
• Brain * physiopathology   diagnostic imaging   MeSH
• Nervous System Diseases * physiopathology   diagnostic imaging   MeSH
• Attention physiology   MeSH
• Heart Rate physiology   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Young Adult MeSH
• Male MeSH
• Female MeSH
• Publication type
• Journal Article MeSH

BACKGROUND: Patients with gastro-oesophageal adenocarcinoma with tumour-positive lymph nodes (ypN+) or positive surgical margins (R1) following neoadjuvant chemotherapy and resection are at high risk of recurrence. Adjuvant nivolumab is effective in oesophageal/oesophagogastric junction cancer and residual pathological disease following chemoradiation and surgery. Immune checkpoint inhibition has shown efficacy in advanced gastro-oesophageal cancer. We hypothesised that nivolumab/ipilimumab would be more effective than adjuvant chemotherapy in high-risk (ypN+ and/or R1) patients with gastro-oesophageal adenocarcinoma following neoadjuvant chemotherapy and resection. PATIENTS AND METHODS: VESTIGE was an academic international, multicentre, open-label, randomised phase II trial evaluating the efficacy of adjuvant nivolumab/ipilimumab versus chemotherapy in gastro-oesophageal adenocarcinoma at high risk of recurrence. Patients were randomised 1 : 1 to receive standard adjuvant chemotherapy (same regimen as neoadjuvant) or nivolumab 3 mg/kg intravenously (i.v.) every 2 weeks plus ipilimumab 1 mg/kg i.v. every 6 weeks for 1 year. Key inclusion criteria included ypN+ and/or R1 status after neoadjuvant chemotherapy plus surgery. The primary endpoint was disease-free survival in the intent-to-treat population. Secondary endpoints included overall survival, locoregional and distant failure rates, and safety according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. RESULTS: The independent Data Monitoring Committee reviewed data from 189 of the planned 240 patients in June 2022 and recommended stopping recruitment due to futility. At the time of final analysis, median follow-up was 25.3 months for 195 patients (98 nivolumab/ipilimumab and 97 chemotherapy). Median disease-free survival for the nivolumab/ipilimumab group was 11.4 months [95% confidence interval (CI) 8.4-16.8 months] versus 20.8 months (95% CI 15.0-29.9 months) for the chemotherapy group, hazard ratio 1.55 (95% CI 1.07-2.25, one-sided P = 0.99). The 12-month disease-free survival rates were 47.1% and 64.0%, respectively. There were no toxicity concerns or excess early discontinuations. CONCLUSION: Nivolumab/ipilimumab did not improve disease-free survival compared with chemotherapy in patients with ypN+ and/or R1 gastro-oesophageal adenocarcinoma following neoadjuvant chemotherapy and surgery.

• MeSH
• Adenocarcinoma * pathology   drug therapy   therapy   MeSH
• Chemotherapy, Adjuvant methods   MeSH
• Adult MeSH
• Gastrectomy MeSH
• Esophagogastric Junction * pathology   MeSH
• Immunotherapy methods   MeSH
• Ipilimumab administration & dosage   therapeutic use   MeSH
• Middle Aged MeSH
• Humans MeSH
• Neoplasm Recurrence, Local * pathology   prevention & control   drug therapy   epidemiology   MeSH
• Esophageal Neoplasms * pathology   drug therapy   therapy   MeSH
• Stomach Neoplasms * pathology   drug therapy   therapy   surgery   MeSH
• Neoadjuvant Therapy * methods   adverse effects   MeSH
• Nivolumab administration & dosage   therapeutic use   MeSH
• Disease-Free Survival MeSH
• Antineoplastic Combined Chemotherapy Protocols * therapeutic use   MeSH
• Aged MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Clinical Trial, Phase II MeSH
• Multicenter Study MeSH
• Randomized Controlled Trial MeSH

BACKGROUND: Androgen-receptor signaling inhibitors (ARSIs) significantly improve survival in systemic therapy for advanced/metastatic prostate cancer (PCa) patients; however possible central nervous system (CNS) toxicity is an unaddressed concern. We aimed to assess and compare the incidence of CNS-related adverse events (AEs) secondary to the treatment of PCa patients with different ARSIs. MATERIALS: In August 2023, a comprehensive seach was conducted in three databases for randomized controlled trials (RCTs) of PCa patients receiving ARSIs plus ADT. The primary endpoints included mental impairment, cognitive impairment, seizure, fatigue, and falls. RESULTS: Twenty-six RCTs, comprising 20,328 patients, were included in meta-analyses and network meta-analyses (NMAs). ARSIs increased the risk of mental impairment (RR: 1.72; 95% CI, 1.09-2.71), cognitive impairment (RR: 2.25; 95% CI, 1.78-2.86), seizure (RR: 2.20, 95% CI, 1.09-4.45), fatigue (RR: 1.31, 95% CI, 1.20-1.43), and falls (RR: 2.07, 95% CI, 1.60-2.67) compared to standard of care (SOC). Based on NMAs, Enzalutamide showed a significant increase in risk for all assessed CNS-related AEs, while Abiraterone demonstrated significant risk increases in cognitive impairment, fatigue, and falls. Conversely, Darolutamide did not exhibit significant increases in risk for any CNS-related AEs, except for fatigue. CONCLUSIONS: The addition of ARSIs to ADT increased all examined CNS-related AEs compared to SOC. Each ARSI is associated with a distinct profile of CNS-related AEs. Careful patient selection and monitoring for CNS sequelae is necessary to achieve the best quality of life in patients on ARSI + ADT for PCa.

• MeSH
• Androgen Receptor Antagonists * adverse effects   administration & dosage   therapeutic use   MeSH
• Benzamides MeSH
• Phenylthiohydantoin adverse effects   administration & dosage   MeSH
• Humans MeSH
• Prostatic Neoplasms * drug therapy   pathology   MeSH
• Central Nervous System Diseases chemically induced   MeSH
• Nitriles MeSH
• Pyrazoles MeSH
• Randomized Controlled Trials as Topic MeSH
• Network Meta-Analysis as Topic * MeSH
• Check Tag
• Humans MeSH
• Male MeSH
• Publication type
• Journal Article MeSH
• Meta-Analysis MeSH
• Review MeSH
• Systematic Review MeSH

Contemporary situation: The priority of nursing care for a newborn in the delivery room is to ensure its safety, and clinical observation and instrumental monitoring can be used for this purpose. Early education in the prenatal period allows the mother and accompanying person to be involved in the safe care of the newborn. Goal: The main goal of this research was to map the nursing care of newborns in the delivery room immediately after birth, emphasising safety and preventing sudden unexpected postnatal collapse (SUPC). Methods: A semi-structured interview with nursing staff caring for newborns in delivery rooms in selected hospitals in South Bohemia (n1 = 21) was used for the qualitative research. The staff were also trained in using the RAPPT (Respiratory, Activity, Perfusion, Position and Tone) scoring system to assess the risk of SUPC and asked about the possibility of its use in practice in delivery rooms (n2 = 12). Results: Based on data analysis, we identified some key areas: Practical procedures of nursing staff in delivery rooms in SUPC prevention, Implementation of assessment tools and monitoring in SUPC prevention, Education and involvement of mothers after childbirth in the SUPC prevention system during skin-to-skin contact in the delivery room, and Possibilities of using the RAPPT scale in newborn care in the delivery room. Conclusion: The need to assess the newborn after birth using the Apgar score to ensure bonding does not correspond to the condition of the newborn. Newborns are calmer during skin-to-skin contact, and other monitoring of the child’s safe adaptation is needed.

Kontaminace pitných vod původci virové gastroenteritidy (př. noroviry, rotaviry, adenoviry) představuje ve vodním hospodářství výzvu, zejména při ochraně zdrojů surové vody a dezinfekci pitné vody. V této práci mapujeme výskyt a možnosti odstraňování virových původců gastroenteritidy v oběhovém vodním hospodářství s cílem omezit riziko ohrožení veřejného zdraví v důsledku virové kontaminace. Enterické viry se do odpadních vod dostávají stolicí infikovaných jedinců. Při konvenčním mechanicko‐biologickém čištění odpadních vod jsou odstraňovány jen částečně a společně s viry v odlehčených odpadních vodách mohou pronikat až do zdrojů surové vody pro úpravny vod. Během procesů úpravy vody dochází ke snižování jejich množství, zejména díky pokročilým oxidačním procesům a dezinfekci. Zatímco v rozvojových zemích je přítomnost těchto virů v distribučních sítích běžná a dlouhodobá, v České republice je jejich výskyt zaznamenáván pouze výjimečně, a to při haváriích, například v Praze v roce 2015 nebo v Libereckém kraji v roce 2022. Z důvodu snížení potenciálních rizik při úpravě vody je vhodné sledovat míru znečištění viry v celém antropogenním vodním cyklu a zamezit únikům nevyčištěné odpadní vody do prostředí.

Contamination of drinking water by viral agents of gastroenteritis (e.g., norovirus, rotavirus, adenovirus) poses a challenge for water management, especially in protecting the freshwater resources and water disinfection. Mapping the occurrence of these viral pathogens within the anthropogenic water cycle can help reduce the risk to public health resulting from viral contamination. Enteric viruses are excreted in the feces of infected individuals and enter the wastewater. During conventional mechanical‐biological wastewater treatment, the excreted viruses are removed only partially and, together with viruses in overflow discharges, may reach raw water sources for drinking water production. During water treatment processes, their concentrations are reduced, especially by advanced oxidation processes and disinfection. The presence of these viruses in distribution systems has been documented even in the Czech Republic during incidents (e.g., Prague 2015, Liberec region 2022) and is a persistent issue in developing countries. Therefore, it is essential to monitor viral contamination throughout the entire anthropogenic water cycle and to prevent the release of untreated wastewater into the environment.

UNLABELLED: Methotrexate is used to manage moderate to severe psoriasis and psoriatic arthritis. Methotrexate acts by inhibiting the enzymes involved in nucleotide synthesis. Methotrexate polyglutamates (MTXPGs) have a higher potency to inhibit Dihydrofolate reductase (DHFR), 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC), and thymidylate synthase (TS), compared to naïve methotrexate. Among all the MTXPGs, methotrexate polyglutamate three (MTXPG-3) is a more potent inhibitor of DHFR, ATIC, and TS enzymes. MTXPG-3 is anticipated to allow therapeutic drug monitoring in immune-mediated inflammatory diseases. We aim to study MTXPG-3 levels as a biomarker for both efficacy and adverse events among psoriatic patients treated with methotrexate monotherapy. We used the LC-MS/MS (Liquid Chromatography Mass Spectrophotometry) system for measuring erythrocyte MTXPG-3. We recruited 106 patients with psoriasis who were treated with methotrexate. Sixty-one of them had psoriatic arthritis (concomitant or in the past). The mean age was 45.08 ± 13.04 years. After twenty-four weeks of methotrexate treatment, 73(69%) were responders, and 33(31%) were non-responders. Thirty-nine (36%) experienced adverse effects, and 67(64%) did not experience any adverse effects. We observed a significant positive correlation between erythrocyte MTXPG-3 and methotrexate dose per week at weeks 12 and 16 but not at week 24. Erythrocyte MTXPG-3 did not correlate with response or adverse effects. It can be used as a marker of compliance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12291-024-01269-x.

• Publication type
• Journal Article MeSH

BACKGROUND: Androgen-receptor pathway inhibitors (ARPIs) have dramatically changed the management of advanced/metastatic prostate cancer (PCa). However, their cardiovascular toxicity remains to be clarified. OBJECTIVE: To analyze and compare the risks of cardiovascular events secondary to treatment of PCa patients with different ARPIs. METHODS: In August 2023, we queried PubMed, Scopus, and Web of Science databases to identify randomized controlled studies (RCTs) that analyze PCa patients treated with abiraterone, apalutamide, darolutamide, and enzalutamide. The primary outcomes of interest were the incidence of cardiac disorder, heart failure, ischemic heart disease (IHD), atrial fibrillation (AF), and hypertension. Network meta-analyses (NMAs) were conducted to compare the differential outcomes of each ARPI plus androgen deprivation therapy (ADT) compared to standard of care (SOC). RESULTS: Overall, 26 RCTs were included. ARPIs were associated with an increased risk of cardiac disorders (RR: 1.74, 95% CI: 1.13-2.68, p = 0.01), heart failure (RR: 2.49, 95% CI: 1.05-5.91, p = 0.04), AF (RR: 2.15, 95% CI: 1.14-4.07, p = 0.02), and hypertension (RR: 2.06, 95% CI: 1.67-2.54, p < 0.01) at grade ≥3. Based on NMAs, abiraterone increased the risk of grade ≥3 cardiac disorder (RR:2.40, 95% CI: 1.42-4.06) and hypertension (RR:2.19, 95% CI: 1.77-2.70). Enzalutamide was associated with the increase of grade ≥3 AF(RR: 3.17, 95% CI: 1.05-9.58) and hypertension (RR:2.30, 95% CI: 1.82-2.92). CONCLUSIONS: The addition of ARPIs to ADT increases the risk of cardiac disorders, including IHD and AF, as well as hypertension. Each ARPI exhibits a distinct cardiovascular event profile. Selecting patients carefully and vigilant monitoring for cardiovascular issues is imperative for those undergoing ARPI + ADT treatment.

• MeSH
• Androstenes MeSH
• Androgen Receptor Antagonists * adverse effects   therapeutic use   MeSH
• Benzamides adverse effects   MeSH
• Phenylthiohydantoin MeSH
• Cardiovascular Diseases * chemically induced   epidemiology   MeSH
• Humans MeSH
• Prostatic Neoplasms * drug therapy   pathology   MeSH
• Nitriles adverse effects   MeSH
• Randomized Controlled Trials as Topic MeSH
• Check Tag
• Humans MeSH
• Male MeSH
• Publication type
• Journal Article MeSH
• Network Meta-Analysis MeSH
• Systematic Review MeSH

Farmakogenetické (PGx) vyšetření představuje slibný nástroj pro optimalizaci psychiatrické farmakoterapie. Svým potenciálem může přispět ke zvýšení její účinnosti a snížení rizika vzniku nežádoucích účinků. Ekonomická limitace v podobě vyšší ceny vyšetření vyžaduje cílenější výběr pacientů, tento přístup však v praxi zatím chybí. Za tím účelem byl klinickými farmaceutkami v Psychiatrické nemocnici Bohnice vyvinut skórovací systém CYPRI (CYP pharmacogenetic risk score) identifikující pacienty, kteří by mohli mít z PGx vyšetření největší prospěch. Cílem pilotní studie bylo pak zhodnotit účinnost a efektivitu skórovacího systému CYPRI při výběru pacientů pro PGx vyšetření v kontextu následně uskutečněných a klinicky významných změn v jejich medikaci. Do pilotní studie, která probíhala mezi lednem 2024 a březnem 2025, bylo zařazeno 23 pacientů (průměrný věk 38 let, 74 % mužů). Vzorek zahrnoval hospitalizované pacienty s širokým spektrem psychiatrických diagnóz, včetně schizofrenie, bipolární a schizoafektivní poruchy, deprese i úzkostných poruch. Pacienti, u kterých bylo PGx indikováno lékařem a/nebo klinickým farmaceutem a kteří v CYPRI skórovali alespoň jedním bodem, podstoupili po souhlasu PGx vyšetření. Následně u nich byla provedena analýza dopadu výsledku tohoto vyšetření na úpravy v medikaci. Byla zjištěna statisticky významná korelace (t = 2,733; p = 0,0063) mezi hodnotami CYPRI skóre a následnými klinicky významnými změnami v medikaci. Pacienti s vysokým CYPRI skóre (> 3) také vyžadovali statisticky významně více úprav medikace a monitorace než pacienti s nízkým skóre (≤ 3) (p < 0,05). Tyto výsledky potvrzují, že CYPRI skóre by mohlo v budoucnu sloužit jako strukturovaný a nákladově efektivní nástroj pro výběr vhodných kandidátů na PGx vyšetření, zejména v oboru psychiatrie. Širší použití CYPRI skóre v praxi prozatím limituje, i přes slibné výsledky z pilotní studie, relativně malá velikost vzorku. Pro potvrzení těchto výstupů je zapotřebí další výzkum na větších kohortách.

Pharmacogenetic (PGx) testing is a promising tool for optimizing psychiatric pharmacotherapy by improving its effectiveness and reducing the risk of adverse effects. However, its higher cost necessitates a more selective approach to patient screening, which is currently lacking in clinical practice. To address this gap, clinical pharmacists at Bohnice Psychiatric Hospital developed a CYPRI (CYP Pharmacogenetic Risk Score) scoring system to identify patients who would benefit the most from PGx testing. This pilot study aimed to assess the effectiveness and efficiency of the CYPRI scoring system in selecting patients for PGx testing, focusing on clinically significant medication adjustments that followed. Our study was conducted from January 2024 to March 2025 and included 23 hospitalized patients (mean age: 38 years; 74% male) with a range of psychiatric diagnoses, including schizophrenia, bipolar disorder, schizoaffective disorder, depression, and anxiety disorders. Pharmacogenetic testing was offered to patients following an initial indication by a psychiatrist and/or clinical pharmacist, provided they scored at least one point on the CYPRI scale. Upon providing an informed consent, they underwent the PGx testing. The resulting impact on medication adjustments was analyzed. A statistically significant correlation was found between the CYPRI scores and clinically significant medication changes (t = 2.733; p = 0.0063). Additionally, patients with high CYPRI scores (> 3) required significantly more medication adjustments and monitoring than those with low scores (≤ 3) (p < 0.05). These findings suggest that the CYPRI score could serve as a structured and cost-effective tool for identifying suitable candidates for PGx testing, especially in psychiatry. Despite these promising results, the relatively small sample size remains a limitation for the broader implementation of the CYPRI score. Further research with larger cohorts is needed to validate these findings.

Úvod: Plicní sekvestrace je vzácná vrozená anomálie dolních dýchacích cest, která je většinou diagnostikována už v dětském věku. Jde o plicní parenchym, který má anomální nebo chybějící komunikaci s tracheobronchiálním stromem. Cévní zásobení není napojeno na plicní oběh, ale pochází ze systémového oběhu. Intralobární plicní sekvestrací se rozumí plicní sekvestr, který má společnou pleuru s normálním parenchymem. Naopak extralobární sekvestr má svou vlastní viscerální pleuru, která nesouvisí s normální plící. Extralobární sekvestrace na rozdíl od intralobární většinou nemá infekční projevy, protože chybí napojení na tracheobronchiální strom. Naopak se může projevit hypoxií, kardiálním selháním či vzácně torzí sekvestru. Častěji však jde o náhodný asymptomatický nález. Vedoucí úlohu v diagnostice má v současnosti CT, které umožňuje zobrazení přívodných cév. Metodou léčby je chirurgická resekce, hlavně jako prevence krvácení či maligního zvratu tkáně. Resekce také poskytne materiál pro bioptické vyšetření. Kazuistika: 68letá pacientka s nefropatií byla v režii nefrologa indikována k ultrasonografii břicha, kde byl náhodně zjištěn tumor v retroperitoneu vlevo. Bylo doplněno CT vyšetření a poté byla indikována k exstirpaci tumoru pro podezření na neurogenní tumor, avšak histologicky šlo o extralobární plicní sekvestraci. Další průběh pak nebyl nijak komplikován. Propuštěna do domácí péče byla 5. pooperační den. Závěr: Kazuistikou chceme prezentovat velmi raritní diagnózu, která je o to vzácnější, že byla nalezena u dospělé pacientky.

Introduction: Pulmonary sequestration is a rare congenital anomaly of the lower respiratory tract, usually diagnosed in childhood. It involves lung parenchyma that has abnormal or absent communication with the tracheobronchial tree. The blood supply is not connected to the pulmonary circulation but comes from the systemic circulation. Intralobar pulmonary sequestration refers to pulmonary sequestration that shares a common pleura with normal parenchyma. In contrast, extralobar sequestration has its own visceral pleura that is not continuous with the normal lung. Extralobar pulmonary sequestration, unlike intralobar pulmonary sequestration, typically does not present with infectious manifestations due to the absence of a connection to the tracheobronchial tree. Instead, it may manifest as hypoxia, cardiac failure, or rarely, torsion of the sequestrum. However, it is more often an incidental asymptomatic finding. Computed tomography currently plays a leading role in diagnosis, enabling visualization of the feeding vessels. Surgical resection is the mainstay of the treatment, primarily to prevent hemorrhage or malignant transformation of the tissue. Resection also provides material for biopsy examination. Case report: A 68-year-old patient with nephropathy was referred by her nephrologist for abdominal ultrasound, which incidentally detected a tumor in the left retroperitoneum. A CT scan was performed, and the patient was then referred for tumor excision due to suspicion of a neurogenic tumor. Postoperatively, she was monitored in the intensive care unit with oxygen therapy for hypoxemia. The further course was uncomplicated. She was discharged home on postoperative day 5. Conclusion: We present a case of this very rare diagnosis, which is even rarer in an adult patient.

• MeSH
• Respiratory System Abnormalities surgery   diagnostic imaging   MeSH
• Bronchopulmonary Sequestration * surgery   diagnostic imaging   MeSH
• Humans MeSH
• Retroperitoneal Neoplasms * surgery   diagnostic imaging   MeSH
• Aged MeSH
• Congenital Abnormalities MeSH
• Rare Diseases MeSH
• Check Tag
• Humans MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Case Reports MeSH
• Research Support, Non-U.S. Gov't MeSH